Madrigal (MDGL) MGL-3196 Delivers Positive Phase II HeFH Data

Madrigal

BioInvest News – Madrigal (MDGL) – MGL-3196 Delivers Positive Phase II HeFH Data – MDGL has released positive top-line HeFH Phase II data. The trial enrolled 116 patients who were not at their LDL-C goal and were randomized in a 2:1 ratio to receive either MGL-3196 or placebo, in addition to their current cholesterol lowering regimen, which included approximately 75% taking high intensity statins (20/40 mg rosuvastatin or 80 mg atorvastatin), and about 2/3 of patients also taking ezetimibe.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.